Strides Pharma Science Ltd Valuation Improves Amid Strong Market Performance

Valuation Metrics and Their Implications

Strides Pharma currently trades at a price of ₹911.40, up 2.07% from the previous close of ₹892.95. The stock’s 52-week range spans from ₹551.00 to ₹1,024.90, indicating significant volatility but also substantial upside potential. The recent valuation grade upgrade from very attractive to attractive is primarily driven by its price-to-earnings (P/E) ratio of 15.23 and price-to-book value (P/BV) of 3.05. These figures suggest the stock is reasonably priced relative to its earnings and net asset value, especially when compared to its peers.

In contrast, many competitors in the Pharmaceuticals & Biotechnology sector are trading at markedly higher multiples. For instance, Ajanta Pharma’s P/E ratio stands at 38.39, Emcure Pharma at 31.58, and Gland Pharma at 32.37, all classified as expensive. More strikingly, companies like Astrazeneca Pharma and Wockhardt command P/E ratios exceeding 100 and 160 respectively, categorised as very expensive. This disparity underscores Strides Pharma’s relative valuation appeal.

Enterprise Value Multiples and Profitability Metrics

Beyond P/E and P/BV, Strides Pharma’s enterprise value to EBITDA (EV/EBITDA) ratio is 11.08, which is modest compared to peers such as J B Chemicals & Pharmaceuticals at 29.66 and Sai Life Sciences at 35.07. The EV to EBIT ratio of 14.19 further supports the notion of reasonable valuation. These multiples indicate that investors are paying a fair price for the company’s operating earnings, reflecting a balanced risk-reward profile.

Profitability metrics also bolster the stock’s attractiveness. The company’s return on capital employed (ROCE) is 15.60%, and return on equity (ROE) is 15.82%, both healthy indicators of efficient capital utilisation and shareholder value creation. While the dividend yield remains modest at 0.44%, the focus for investors appears to be on growth and operational efficiency rather than income generation.

Performance Relative to Market Benchmarks

Strides Pharma’s stock performance has been robust over multiple time horizons, significantly outpacing the Sensex benchmark. Over the past year, the stock has delivered a 49.41% return compared to Sensex’s 2.71%. The three-year return is particularly impressive at 554.45%, dwarfing the Sensex’s 28.58% gain. Even over five years, Strides Pharma has returned 126.55%, well ahead of the Sensex’s 49.70%. These figures highlight the company’s strong growth trajectory and resilience in a competitive sector.

Comparative Valuation: Strides Pharma vs Peers

When analysing valuation in the context of the broader Pharmaceuticals & Biotechnology sector, Strides Pharma’s metrics stand out for their relative moderation. The company’s PEG ratio is currently 0.00, signalling either a lack of consensus on growth estimates or a highly favourable valuation relative to earnings growth. In comparison, peers such as Ajanta Pharma and J B Chemicals & Pharmaceuticals have PEG ratios of 2.96 and 3.22 respectively, indicating more expensive valuations relative to growth prospects.

Strides Pharma’s market capitalisation is classified as small-cap, which often entails higher volatility but also greater growth potential. The company’s mojo score has improved to 56.0 with a mojo grade upgrade from Sell to Hold as of 5 March 2026, reflecting enhanced investor confidence and improved fundamentals. This upgrade is a significant development, signalling that the stock is transitioning from a riskier proposition to a more stable investment option within its sector.

Price Momentum and Trading Range

The stock’s recent price momentum has been positive, with a day’s high of ₹922.20 and a low of ₹879.10 on 13 March 2026. This intraday volatility is typical for small-cap stocks but the upward trend is encouraging. The current price remains below the 52-week high of ₹1,024.90, suggesting room for appreciation if the company continues to deliver on growth and profitability metrics.

Risks and Considerations

Despite the favourable valuation shift, investors should remain mindful of sector-specific risks such as regulatory changes, pricing pressures, and competitive dynamics. The pharmaceutical industry is subject to stringent compliance requirements and patent expiries, which can impact earnings visibility. Additionally, the relatively low dividend yield indicates that the company is prioritising reinvestment over shareholder payouts, which may not suit income-focused investors.

Outlook and Investor Takeaway

Strides Pharma Science Ltd’s recent valuation upgrade and improved mojo grade reflect a company on a positive trajectory. The attractive P/E and P/BV ratios relative to peers, combined with solid profitability metrics and strong historical returns, make it a noteworthy candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector. While the stock remains a small-cap with inherent volatility, its valuation repositioning suggests a more balanced risk-reward profile than before.

Investors should continue to monitor quarterly earnings, regulatory developments, and sector trends to gauge the sustainability of this valuation shift. Given the company’s current fundamentals and market positioning, Strides Pharma appears well-placed to capitalise on growth opportunities while maintaining operational efficiency.

Summary of Key Financial Metrics

• P/E Ratio: 15.23 (Attractive)
• Price to Book Value: 3.05
• EV to EBIT: 14.19
• EV to EBITDA: 11.08
• ROCE: 15.60%
• ROE: 15.82%
• Dividend Yield: 0.44%
• Mojo Score: 56.0 (Hold, upgraded from Sell on 5 Mar 2026)
• Market Cap: Small-cap
• 1-Year Return: 49.41% vs Sensex 2.71%

These figures collectively underpin the stock’s renewed price attractiveness and improved investment appeal within its sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →